PLSE
Pulse Biosciences, Inc. · Healthcare
19.12
16.65%(-3.82)
Market OpenLast Updated: — ET
52W L: $12.5652W H: $26.30
$19.22
CHG+1.41 (+7.92%)
H$23.66
L$17.70
VOL4.9M
PLSE (1h)
Pulse Biosciences, Inc. · Healthcare
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced enrollment of the first patients in its NANOPULSE-AF study, a prospective, multicenter, IDE pivotal clinical investigation currently evaluating the nPulse™ Cardiac Catheter System for treating recurrent, drug-resistant, symptomatic paroxysmal atrial fibrillation (AF). The first seven patients in this study w.
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced plans to present at the upcoming 25th Annual Needham Virtual Healthcare Conference. Pulse Biosciences' Management is scheduled to present on Thursday, April 16, 2026, at 9:30 am ET. A live and recorded webcast of the presentation will be available on the “Events Calendar and Presentations” page of the company.
Pulse Biosciences pivots to its nPulse AFib system after strong clinical results, ramping investment to accelerate development and future commercialization.
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced a new strategic alignment to prioritize and accelerate the development and future commercialization of its nPulse Cardiac Catheter Ablation System. “The European feasibility data from over 150 patients sends a definitive message,” said Bob Duggan, Co-Chairman of Pulse Biosciences. “The nPulse clinical perform.
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced first patient enrollments in the multi-center first-in-human feasibility study of the Company's nPulse™ Vybrance™ Percutaneous Electrode System for treatment of T1N0M0 papillary thyroid microcarcinoma (PTM), a small, slow-growing, and most common form of thyroid cancer. The i.
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced clinical data on outcomes durability from the nPulse Vybrance Percutaneous Electrode System First-in-Human ablation study of benign thyroid nodules using nsPFA energy. The long-term follow-up from this study demonstrates significant and sustained volume reduction of treated benig.
UECKER DARRIN
director, officer: Chief Technology Officer
100,000 SH @ $0.00
2026-03-23
Danahy Kevin Patrick
officer: Chief Commercial Officer
5,000 SH @ $1.53
2026-02-18
Danahy Kevin Patrick
officer: Chief Commercial Officer
5,000 SH @ $1.53
2026-02-18
Danahy Kevin Patrick
officer: Chief Commercial Officer
5,000 SH @ $23.64
2026-02-18
Danahy Kevin Patrick
officer: Chief Commercial Officer
20,000 SH @ $1.53
2026-02-12
Danahy Kevin Patrick
officer: Chief Commercial Officer
20,000 SH @ $1.53
2026-02-13
Danahy Kevin Patrick
officer: Chief Commercial Officer
20,000 SH @ $1.53
2026-02-17
Danahy Kevin Patrick
officer: Chief Commercial Officer
20,000 SH @ $1.53
2026-02-17